Natural history investigation will deploy latest advances to identify biomarkers, targets for early therapy A new clinical study led by the National Eye Institute (NEI), part of the National Institutes of Health, will follow 500 people over five years to learn more about the natural history of early age-related macular degeneration (AMD). By using the [Read More]
Category: Latest News
New Stem Cell Therapy Treats Macular Degeneration
A new procedure reported in the current issue of Nature Biotechnology has been shown to be a safe and effective method for introducing stem cells into the retina. Implantation of a specially engineered patch of retinal pigment epithelium (RPE) cells derived from stem cells has restored some vision in two people with sight loss from [Read More]
Accessible Prescription Labels Offer Convenience and Safety
People who cannot read their prescription labels often make medication errors, sometimes leading to hospitalization or worse. To address this serious issue, several pharmacies now provide accessible prescription labels. Provided by En-Vision America, “Scriptability” labels provide a safe and convenient way to access prescription information for individuals who cannot read standard print. The labels are [Read More]
Aging Can Cause Eye Problems Other Than Low Vision Disease
by Ellen Troyer, MT MA CEO & Chief Research Officer, Biosyntrx Just as hair turns gray with age, bladders weaken and memories lapse, our eyes, too, undergo a metamorphosis. Although these changes are all part of normal aging, some set the stage for more serious eye problems. As eyes age, eyelid muscles weaken, and skin becomes [Read More]
New Anti-Ang2 Drug for Wet AMD Showing Promise
It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have [Read More]